Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind trial of BIBF 1120 (150 mg BID) in idiopathic pulmonary fibrosis
2010-024252-29Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BIBF 1120 with Placebo (2 arms). Primary endpoint: Annual rate of decline in forced vital capacity. Started Feb 2011; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2010-024252-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024252-29.